Development-stage drugmaker and Motley Fool Hidden Gems Pay Dirt pick MannKind
For any diabetes treatment, the gold standard for measuring a compound's effectiveness is how well it works to lower a patient's long-term blood sugar level (what are known as HbA1c levels). In this one-year study, Technosphere performed at least equally as well at controlling diabetics' blood sugar levels as long-approved insulin treatment Novolog from Novo Nordisk
Even more important considering what happened earlier this year, MannKind didn't report any lung neoplasms (tumors, benign or not) in the study. This is the suspected adverse event that affected Exubera -- Nektar Therapeutics
Overall, though, this study can be considered a success on the efficacy side. It is only the first of three phase 3 trials for which MannKind will be announcing data over the coming months. MannKind still expects to file a marketing application for Technosphere with the FDA late this year or early next year, so investors won't have to wait much longer for the rest of the pivotal phase 3 data to come in.
It's hoped a clearer picture of Technosphere's safety profile will emerge by the end of the year. That will make or break the whole deal.
More from The Motley Fool
Here's Why MannKind Corporation Remained Stuck in Reverse and Lost 24% in February
MannKind's reverse stock split gave investors the blues.
Why MannKind Corporation Stock Is Sinking Today
The biopharma's reverse split isn't a hit with investors.
3 Stocks to Avoid in Biotech
Biotech stocks are known for their high growth, but they can also be toxic for your portfolio if you don't invest wisely.